Aurinia Pharmaceuticals Inc. AUPH

On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]

Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

Aurinia Pharmaceuticals Inc. recently reported second-quarter 2026 results showing higher revenue and earnings year over year, reiterated its 2026 revenue and net product sales guidance, completed a large share buyback program, and finalized a settlement with Teva Pharmaceuticals that delays U.S. generic voclosporin entry until at least December 7, 2036. The Teva settlement meaningfully strengthens Aurinia’s intellectual property protection around voclosporin, potentially extending its U.S...

Aurinia Pharmaceuticals stock has delivered a 74.2% return over the past three years, and the broader valuation checks currently lean toward the shares being on the cheap side rather than fully priced. With fresh progress in its lupus nephritis franchise and pipeline, investors now face the question of whether that past gain already reflects the improving outlook or if the current price still leaves room based on fundamentals. Aurinia Pharmaceuticals has returned 74.2% over the last three...

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.

EDMONTON, Alberta, August 19, 2026--Aurinia Settles Patent Litigation with Teva

ROCKVILLE, Md. & EDMONTON, Alberta, August 06, 2026--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta, July 06, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at

Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AUPH. Aurinia Pharmaceuticals Inc.’s share was trading at $18.62 as of June 24th. AUPH’s trailing and forward P/E were 8.27 and 23.42 respectively according to Yahoo […]